Supplementary Figure 1. Imaging of metalloprotease activity in human tumor cells.

HN-26 human oropharyngeal squamous carcinoma cells were incubated with 90 nM (5 μg/ml) LF/β-Lac (a-f), and 26 nM (2 μg/ml) PrAg-U7 (b), 26 nM (2 μg/ml) PrAg-L1 (c), 26 nM PrAg-L1 and 2 μM BB-94 (d), 26 nM PrAg-L1 and 2 μM BB-2516 (e), and 26 nM PrAg-L1 and 450 nM (10 μg/ml) TIMP-2 (f). CCF2/AM (1.5 μM) was added, and the cells were examined by fluorescence microscopy. Imaging of metalloprotease activity is demonstrated by blue fluorescent cells after treatment with LF/β-Lac in combination with PrAg-L1 (c), but not LF/β-Lac alone (a) or LF/β-Lac with PrAg-U7 (b). Blue fluorescence due to protease activity is inhibited by the metalloprotease inhibitors, BB-94 (d), BB-2516 (e), and TIMP-2 (f). Size bars: 100 μm.